XML 35 R10.htm IDEA: XBRL DOCUMENT
v3.23.1

Grant Income | 12 Months Ended
--- | ---
Dec. 31, 2022
Grant Income |
Grant Income | (4) Grant Income In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of Buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $0 and $36,754 for the years ended December 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $36,754 during the year ended December 31, 2021 and recorded a grant receivable of $0 as of December 31, 2021, and had no unreimbursed, eligible costs incurred under the grant. As of December 31, 2022, there were no remaining funds available under the grant.

X
- References No definition available. + Details
Name: | anvs_NonOperatingIncomeGrantIncomeAbstract
Namespace Prefix: | anvs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the grant income classified as other non-operating income. + References No definition available. + Details
Name: | anvs_OtherNonoperatingIncomeGrantIncomeTextBlock
Namespace Prefix: | anvs_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration